Abstract

Behçet’s disease (BD) is a vasculitis that affects vessels of any size. It is more frequent along the ancient Silk Road, extending from the Far East to the Mediterranean basin. Its etiopathogenesis is complex, and both the innate and adaptive immune systems play a role in recurrent hyperinflammation. The significant association between human leukocyte antigen B-51 and BD indicated a strong genetic background in pathogenesis. Although mucocutaneous involvement is the most common finding, it may present with a broad spectrum of clinical signs and symptoms involving the ocular, vascular, musculoskeletal, neurologic, and gastrointestinal systems. Pediatric cases may present with an incomplete clinical picture of the BD, making diagnosis difficult for the physicians. Several classification criteria have been published so far. In 2015, a classification criteria set for pediatric BD (PEDBD) was established for the first time.

The treatment strategies vary depending on the severity and type of organ involvement. The treatment should be arranged with a multidisciplinary approach according to the organs involved. Also, the possibility of developing morbidity and mortality requires early diagnosis, appropriate treatment, and close follow-up. In this review, we aimed to discuss the etiopathogenesis, clinical findings, diagnostic criteria, and treatment approach of pediatric BD based on current data.

Keywords: Behçet’s disease, pediatric

Copyright and license

Copyright © 2024 The author(s). This is an open-access article published by Aydın Pediatric Society under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Kaya Akca Ü, Bilginer Y. Pediatric Behçet’s disease. Trends in Pediatrics. 2024;5(3):53-9. https://doi.org/10.59213/TP.2024.169

References

  1. Pain CE. Juvenile-onset Behçet's syndrome and mimics. Clin Immunol. 2020;214:108381. https://doi.org/10.1016/j.clim.2020.108381 DOI: https://doi.org/10.1016/j.clim.2020.108381
  2. Nanthapisal S, Klein NJ, Ambrose N, Eleftheriou D, Brogan PA. Paediatric Behçet's disease: a UK tertiary centre experience. Clin Rheumatol. 2016;35:2509-16. https://doi.org/10.1007/s10067-016-3187-z DOI: https://doi.org/10.1007/s10067-016-3187-z
  3. Yildiz M, Haslak F, Adrovic A, et al. Pediatric Behçet's Disease. Front Med (Lausanne). 2021;8:627192. https://doi.org/10.3389/fmed.2021.627192 DOI: https://doi.org/10.3389/fmed.2021.627192
  4. Gheita TA, El-Latif EA, El-Gazzar II, et al. Behçet's disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature. Clin Rheumatol. 2019;38:2565-75. https://doi.org/10.1007/s10067-019-04570-w DOI: https://doi.org/10.1007/s10067-019-04570-w
  5. Alpsoy E, Leccese P, Emmi G, Ohno S. Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach. Front Med (Lausanne). 2021;8:624795. https://doi.org/10.3389/fmed.2021.624795 DOI: https://doi.org/10.3389/fmed.2021.624795
  6. Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Behçet's disease. Orphanet J Rare Dis. 2021;16:352. https://doi.org/10.1186/s13023-020-01620-4 DOI: https://doi.org/10.1186/s13023-020-01620-4
  7. Cakir N, Dervis E, Benian O, et al. Prevalence of Behçet's disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol. 2004;22(Suppl. 34):S53-5.
  8. Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803-6. https://doi.org/10.1046/j.1365-4362.2003.01893.x DOI: https://doi.org/10.1046/j.1365-4362.2003.01893.x
  9. Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet's disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13:57-65. https://doi.org/10.1080/1744666X.2016.1205486 DOI: https://doi.org/10.1080/1744666X.2016.1205486
  10. Pain CE, Beresford MW, Fortune F, et al. Behçet's syndrome in children and young people in the United Kingdom and the Republic of Ireland: a prospective epidemiological study. Rheumatology (Oxford). 2021;60:4728-36. https://doi.org/10.1093/rheumatology/keab084 DOI: https://doi.org/10.1093/rheumatology/keab084
  11. Gallizzi R, Pidone C, Cantarini L, et al. A national cohort study on pediatric Behçet's disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J. 2017;15:84. https://doi.org/10.1186/s12969-017-0213-x DOI: https://doi.org/10.1186/s12969-017-0213-x
  12. Atmaca L, Boyvat A, Yalçındağ FN, Atmaca-Sonmez P, Gurler A. Behçet disease in children. Ocul Immunol Inflamm. 2011;19:103-7. https://doi.org/10.3109/09273948.2011.555592 DOI: https://doi.org/10.3109/09273948.2011.555592
  13. Seyahi E. Behçet's disease: How to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016;30:279-95. https://doi.org/10.1016/j.berh.2016.08.002 DOI: https://doi.org/10.1016/j.berh.2016.08.002
  14. Kim DK, Chang SN, Bang D, Lee ES, Lee S. Clinical analysis of 40 cases of childhood-onset Behçet's disease. Pediatr Dermatol. 1994;11:95-101. https://doi.org/10.1111/j.1525-1470.1994.tb00559.x DOI: https://doi.org/10.1111/j.1525-1470.1994.tb00559.x
  15. Koné-Paut I, Shahram F, Darce-Bello M, et al. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75:958-64. https://doi.org/10.1136/annrheumdis-2015-208491 DOI: https://doi.org/10.1136/annrheumdis-2015-208491
  16. Koné-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135:89-93. https://doi.org/10.1016/s0022-3476(99)70333-1 DOI: https://doi.org/10.1016/S0022-3476(99)70333-1
  17. Leccese P, Alpsoy E. Behçet's Disease: An Overview of Etiopathogenesis. Front Immunol. 2019;10:1067. https://doi.org/10.3389/fimmu.2019.01067 DOI: https://doi.org/10.3389/fimmu.2019.01067
  18. Gül A. Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37:413-8. https://doi.org/10.1007/s00281-015-0502-8 DOI: https://doi.org/10.1007/s00281-015-0502-8
  19. Greco A, De Virgilio A, Ralli M, et al. Behçet's disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17:567-75. https://doi.org/10.1016/j.autrev.2017.12.006 DOI: https://doi.org/10.1016/j.autrev.2017.12.006
  20. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107-19. https://doi.org/10.1038/nrrheum.2017.208 DOI: https://doi.org/10.1038/nrrheum.2017.208
  21. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol. 1997;14:21-32. https://doi.org/10.3109/08830189709116842 DOI: https://doi.org/10.3109/08830189709116842
  22. Behçet H. Uber rezidivierende Aphthose, duruch ein Virus verursachte Geschwre am Mund am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1151.
  23. Yokota K, Hayashi S, Fujii N, et al. Antibody response to oral streptococci in Behçet's disease. Microbiol Immunol. 1992;36:815-22. https://doi.org/10.1111/j.1348-0421.1992.tb02083.x DOI: https://doi.org/10.1111/j.1348-0421.1992.tb02083.x
  24. Mumcu G, Ergun T, Inanc N, et al. Oral health is impaired in Behçet's disease and is associated with disease severity. Rheumatology (Oxford). 2004;43:1028-33. https://doi.org/10.1093/rheumatology/keh236 DOI: https://doi.org/10.1093/rheumatology/keh236
  25. Coit P, Mumcu G, Ture-Ozdemir F, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease. Clin Immunol. 2016;169:28-35. https://doi.org/10.1016/j.clim.2016.06.002 DOI: https://doi.org/10.1016/j.clim.2016.06.002
  26. Consolandi C, Turroni S, Emmi G, et al. Behçet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14:269-76. https://doi.org/10.1016/j.autrev.2014.11.009 DOI: https://doi.org/10.1016/j.autrev.2014.11.009
  27. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287-96. https://doi.org/10.1002/art.24642 DOI: https://doi.org/10.1002/art.24642
  28. Hou S, Yang Z, Du L, et al. Identification of a susceptibility locus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum. 2012;64:4104-13. https://doi.org/10.1002/art.37708 DOI: https://doi.org/10.1002/art.37708
  29. Salmaninejad A, Gowhari A, Hosseini S, et al. Genetics and immunodysfunction underlying Behçet's disease and immunomodulant treatment approaches. J Immunotoxicol. 2017;14:137-51. https://doi.org/10.1080/1547691X.2017.1346008 DOI: https://doi.org/10.1080/1547691X.2017.1346008
  30. Fu Y, Li X, Chen Y, Liu R, Wang R, Bai N. Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris: A case-control study. Medicine (Baltimore). 2018;97:e12828. https://doi.org/10.1097/MD.0000000000012828 DOI: https://doi.org/10.1097/MD.0000000000012828
  31. Reeves E, Elliott T, James E, Edwards CJ. ERAP1 in the pathogenesis of ankylosing spondylitis. Immunol Res. 2014;60:257-69. https://doi.org/10.1007/s12026-014-8576-2 DOI: https://doi.org/10.1007/s12026-014-8576-2
  32. Takeuchi M, Ombrello MJ, Kirino Y, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers. Ann Rheum Dis. 2016;75:2208-11. https://doi.org/10.1136/annrheumdis-2015-209059 DOI: https://doi.org/10.1136/annrheumdis-2015-209059
  33. López de Castro JA, Alvarez-Navarro C, Brito A, Guasp P, Martín-Esteban A, Sanz-Bravo A. Molecular and pathogenic effects of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in MHC-I-associated inflammatory disorders: towards a unifying view. Mol Immunol. 2016;77:193-204. https://doi.org/10.1016/j.molimm.2016.08.005 DOI: https://doi.org/10.1016/j.molimm.2016.08.005
  34. Ombrello MJ, Kastner DL, Remmers EF. Endoplasmic reticulum-associated amino-peptidase 1 and rheumatic disease: genetics. Curr Opin Rheumatol. 2015;27:349-56. https://doi.org/10.1097/BOR.0000000000000189 DOI: https://doi.org/10.1097/BOR.0000000000000189
  35. Kochan G, Krojer T, Harvey D, et al. Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming. Proc Natl Acad Sci U S A. 2011;108:7745-50. https://doi.org/10.1073/pnas.1101262108 DOI: https://doi.org/10.1073/pnas.1101262108
  36. Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet. 2010;42:698-702. https://doi.org/10.1038/ng.625 DOI: https://doi.org/10.1038/ng.625
  37. Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis. 2013;72:1510-6. https://doi.org/10.1136/annrheumdis-2011-200288 DOI: https://doi.org/10.1136/annrheumdis-2011-200288
  38. Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet's disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13:367-73. https://doi.org/10.1111/j.1756-185X.2010.01549.x DOI: https://doi.org/10.1111/j.1756-185X.2010.01549.x
  39. Hamzaoui A, Jaziri F, Ben Salem T, et al. Comparison of clinical features of Behcet disease according to age in a Tunisian cohort. Acta Med Iran. 2014;52:748-51.
  40. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338-47. https://doi.org/10.1111/jdv.12107 DOI: https://doi.org/10.1111/jdv.12107
  41. Yıldız M, Köker O, Adrovic A, Şahin S, Barut K, Kasapçopur Ö. Pediatric Behçet's disease - clinical aspects and current concepts. Eur J Rheumatol. 2020;7:S38-47. https://doi.org/10.5152/eurjrheum.2019.19121 DOI: https://doi.org/10.5152/eurjrheum.2019.19121
  42. Gezgin Yıldırım D, Bakkaloğlu SA, Hasanreisoglu M, Buyan N. Disease activity and outcomes in juvenile Behçet's disease: 10 years' experience of a single centre. Clin Exp Rheumatol. 2020;38(Suppl. 127):105-11.
  43. Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S. Low prevalence of juvenile-onset Behcet's disease with uveitis in East/South Asian people. Br J Ophthalmol. 2009;93:1428-30. https://doi.org/10.1136/bjo.2008.154476 DOI: https://doi.org/10.1136/bjo.2008.154476
  44. Batu ED. Diagnostic/classification criteria in pediatric Behçet's disease. Rheumatol Int. 2019;39:37-46. https://doi.org/10.1007/s00296-018-4208-9 DOI: https://doi.org/10.1007/s00296-018-4208-9
  45. Shahram F, Nadji A, Akhlaghi M, et al. Paediatric Behçet's disease in Iran: report of 204 cases. Clin Exp Rheumatol. 2018;36:135-40.
  46. Karincaoglu Y, Borlu M, Toker SC, et al. Demographic and clinical properties of juvenile-onset Behçet's disease: A controlled multicenter study. J Am Acad Dermatol. 2008;58:579-84. https://doi.org/10.1016/j.jaad.2007.10.452 DOI: https://doi.org/10.1016/j.jaad.2007.10.452
  47. Mendes D, Correia M, Barbedo M, et al. Behçet's disease-a contemporary review. J Autoimmun. 2009;32:178-88. https://doi.org/10.1016/j.jaut.2009.02.011 DOI: https://doi.org/10.1016/j.jaut.2009.02.011
  48. Hu YC, Chiang BL, Yang YH. Clinical Manifestations and Management of Pediatric Behçet's Disease. Clin Rev Allergy Immunol. 2021;61:171-80. https://doi.org/10.1007/s12016-020-08809-2 DOI: https://doi.org/10.1007/s12016-020-08809-2
  49. Borlu M, Ukşal U, Ferahbaş A, Evereklioglu C. Clinical features of Behçet's disease in children. Int J Dermatol. 2006;45:713-6. https://doi.org/10.1111/j.1365-4632.2006.02754.x DOI: https://doi.org/10.1111/j.1365-4632.2006.02754.x
  50. Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric behçet disease in the American Midwest. Am J Ophthalmol. 2008;146:819-27.e2. https://doi.org/10.1016/j.ajo.2008.05.043 DOI: https://doi.org/10.1016/j.ajo.2008.05.043
  51. Sungur GK, Hazirolan D, Yalvac I, et al. Clinical and demographic evaluation of Behçet disease among different paediatric age groups. Br J Ophthalmol. 2009;93:83-7. https://doi.org/10.1136/bjo.2007.137141 DOI: https://doi.org/10.1136/bjo.2007.137141
  52. Kramer M, Amer R, Mukamel M, Snir M, Jaouni T, Friling R. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients. Eye (Lond). 2009;23:2034-41. https://doi.org/10.1038/eye.2008.397 DOI: https://doi.org/10.1038/eye.2008.397
  53. Uluduz D, Kürtüncü M, Yapıcı Z, et al. Clinical characteristics of pediatric-onset neuro-Behçet disease. Neurology. 2011;77:1900-5. https://doi.org/10.1212/WNL.0b013e318238edeb DOI: https://doi.org/10.1212/WNL.0b013e318238edeb
  54. Noel N, Bernard R, Wechsler B, et al. Long-term outcome of neuro-Behçet's disease. Arthritis Rheumatol. 2014;66:1306-14. https://doi.org/10.1002/art.38351 DOI: https://doi.org/10.1002/art.38351
  55. Koné-Paut I. Behçet's disease in children, an overview. Pediatr Rheumatol Online J. 2016;14:10. https://doi.org/10.1186/s12969-016-0070-z DOI: https://doi.org/10.1186/s12969-016-0070-z
  56. Emmi G, Bettiol A, Silvestri E, et al. Vascular Behçet's syndrome: an update. Intern Emerg Med. 2019;14:645-52. https://doi.org/10.1007/s11739-018-1991-y DOI: https://doi.org/10.1007/s11739-018-1991-y
  57. Krause I, Uziel Y, Guedj D, et al. Childhood Behçet's disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford). 1999;38:457-62. https://doi.org/10.1093/rheumatology/38.5.457 DOI: https://doi.org/10.1093/rheumatology/38.5.457
  58. Gürgün C, Ercan E, Ceyhan C, et al. Cardiovascular involvement in Behçet's disease. Jpn Heart J. 2002;43:389-98. https://doi.org/10.1536/jhj.43.389 DOI: https://doi.org/10.1536/jhj.43.389
  59. Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S. Renal Behçet's disease: a cumulative analysis. Semin Arthritis Rheum. 2002;31:317-37. https://doi.org/10.1053/sarh.2002.31721 DOI: https://doi.org/10.1053/sarh.2002.31721
  60. International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078-80. DOI: https://doi.org/10.1016/0140-6736(90)92643-V
  61. Batu ED, Sönmez HE, Sözeri B, Butbul Aviel Y, Bilginer Y, Özen S. The performance of different classification criteria in paediatric Behçet's disease. Clin Exp Rheumatol. 2017;35(Suppl. 108):119-23.
  62. Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 2001;44:2686-92. https://doi.org/10.1002/1529-0131(200111)44:11<2686::aid-art448>3.0.co;2-h DOI: https://doi.org/10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H
  63. Çirkinoğlu MS, Demir S, Bilginer Y, Özen S. Behçet's disease in children: single-center experience. Turk Pediatri Ars. 2019;54:179-84. https://doi.org/10.14744/TurkPediatriArs.2019.15045 DOI: https://doi.org/10.14744/TurkPediatriArs.2019.15045
  64. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-62. https://doi.org/10.1136/ard.2007.080432 DOI: https://doi.org/10.1136/ard.2007.080432
  65. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61-70. https://doi.org/10.1016/j.semarthrit.2010.09.002 DOI: https://doi.org/10.1016/j.semarthrit.2010.09.002
  66. Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. N Engl J Med. 2019;381:1918-28. https://doi.org/10.1056/NEJMoa1816594 DOI: https://doi.org/10.1056/NEJMoa1816594
  67. Benitah NR, Sobrin L, Papaliodis GN. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Semin Ophthalmol. 2011;26:295-303. https://doi.org/10.3109/08820538.2011.588665 DOI: https://doi.org/10.3109/08820538.2011.588665
  68. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018;77:808-18. https://doi.org/10.1136/annrheumdis-2018-213225 DOI: https://doi.org/10.1136/annrheumdis-2018-213225
  69. Petty RE, Laxer RM, Lindsley CB, Wedderburn L. Textbook of pediatric rheumatology. Elsevier Health Sciences; 2015.
  70. Esatoglu SN, Hatemi G. Update on the treatment of Behçet's syndrome. Intern Emerg Med. 2019;14:661-75. https://doi.org/10.1007/s11739-019-02035-1 DOI: https://doi.org/10.1007/s11739-019-02035-1
  71. Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67-74. https://doi.org/10.1016/j.jaut.2015.06.005 DOI: https://doi.org/10.1016/j.jaut.2015.06.005
  72. Ghembaza MEA, Lounici A. Relationship between age at onset and clinical characteristics of Behçet's disease. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27:175-7. DOI: https://doi.org/10.15570/actaapa.2018.37
  73. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76. https://doi.org/10.1097/00005792-200301000-00006 DOI: https://doi.org/10.1097/00005792-200301000-00006
  74. Costagliola G, Cappelli S, Consolini R. Behçet's Disease in Children: Diagnostic and Management Challenges. Ther Clin Risk Manag. 2020;16:495-507. https://doi.org/10.2147/TCRM.S232660 DOI: https://doi.org/10.2147/TCRM.S232660
  75. Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet's disease. Arthritis Rheum. 2010;62:2806-12. https://doi.org/10.1002/art.27568 DOI: https://doi.org/10.1002/art.27568
  76. Mastrolia MV, Bettiol A, Marrani E, et al. Behçet syndrome in children and adults: discovering similarities and differences by a comparative study. Rheumatology (Oxford). 2023;62:SI189-95. https://doi.org/10.1093/rheumatology/keac347 DOI: https://doi.org/10.1093/rheumatology/keac347